The future of peptides in cancer treatment

Kurrikoff, Kaido; Aphkhazava, David; Langel, Ülo

doi:10.1016/j.coph.2019.01.008

Cited by 73 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most importantly, pH-sensitive DDS are considered as suitable carriers for chemotherapeutics [ 44 – 46 ]. Furthermore, peptides also play an important role as active moieties for many diseases, including cancer [ 47 ], peptic ulcer [ 48 ], asthma [ 49 ], cardiovascular diseases [ 50 ], and hypertension [ 51 ]. A particularly important aspect of peptides that contain both hydrophobic and hydrophilic amino acid residues is their amphiphilicity, which plays a crucial role in the self-assembly process [ 52 ].…”

Section: Introductionmentioning

confidence: 99%

pH- and concentration-dependent supramolecular self-assembly of a naturally occurring octapeptide

Ghosh¹,

Fernández²

2020

Beilstein J. Org. Chem.

View full text Add to dashboard Cite

Peptide-based biopolymers represent highly promising biocompatible materials with multiple applications, such as tailored drug delivery, tissue engineering and regeneration, and as stimuli-responsive materials. Herein, we report the pH- and concentration-dependent self-assembly and conformational transformation of the newly synthesized octapeptide PEP-1. At pH 7.4, PEP-1 forms β-sheet-rich secondary structures into fractal-like morphologies, as verified by circular dichroism (CD), Fourier-transform infrared (FTIR) spectroscopy, thioflavin T (ThT) fluorescence spectroscopy assay, and atomic force microscopy (AFM). Upon changing the pH value (using pH 5.5 and 13.0), PEP-1 forms different types of secondary structures and resulting morphologies due to electrostatic repulsion between charged amino acids. PEP-1 can also form helical or random-coil secondary structures at a relatively low concentration. The obtained pH-sensitive self-assembly behavior of the target octapeptide is expected to contribute to the development of novel drug nanocarrier assemblies.

show abstract

Section: Introductionmentioning

confidence: 99%

pH- and concentration-dependent supramolecular self-assembly of a naturally occurring octapeptide

Ghosh¹,

Fernández²

2020

Beilstein J. Org. Chem.

View full text Add to dashboard Cite

show abstract

“…At the same time, while the role of peptides in the development of innovative therapies and new diagnostic tools for oncological diseases is still marginal, it is important to note that in 2018 about 35 peptides were in different stages of clinical testing and four molecules have been approved for the clinical use from 2000 to 2016 [4].…”

Section: Introductionmentioning

confidence: 99%

How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs

et al. 2020

View full text Add to dashboard Cite

The early and late development of new anticancer drugs, small molecules or peptides can be slowed down by some issues such as poor selectivity for the target or poor ADME properties. Computer-aided drug design (CADD) and target drug delivery (TDD) techniques, although apparently far from each other, are two research fields that can give a significant contribution to overcome these problems. Their combination may provide mechanistic understanding resulting in a synergy that makes possible the rational design of novel anticancer based therapies. Herein, we aim to discuss selected applications, some also from our research experience, in the fields of anticancer small organic drugs and peptides.

show abstract

“…This technique is commonly applied in preclinical studies in GBM orthotopic models [ 38 ]; however, it has technical limitations and complications that make this type of therapy ineffective in clinical studies [ 39 ], requiring the development of structures that are safely administered in systemic circulation, are able to cross the BBB, and allow effective bioavailability of anti-tumor/anti-angiogenic drugs [ 35 , 36 , 40 ]. In this regard, a method that has been remarkable and promises to improve the delivery of bioactive compounds is the coupling of different types of nanostructured materials, such as a peptide based on polymeric structures [ 41 , 42 ], lipid-based liposomal formulations [ 43 , 44 , 45 , 46 , 47 ], and nanoshells [ 48 ]. These nanoformulations have the potential to provide clinically minimally invasive and targeted delivery of drugs with proven antiangiogenic effects or whose therapeutic potential is being pre-clinically tested [ 35 , 36 , 40 ].…”

Section: Introductionmentioning

confidence: 99%

Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations

Rego

Alves

Nucci

et al. 2020

IJMS

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive tumor type whose resistance to conventional treatment is mediated, in part, by the angiogenic process. New treatments involving the application of nanoformulations composed of encapsulated drugs coupled to peptide motifs that direct drugs to specific targets triggered in angiogenesis have been developed to reach and modulate different phases of this process. We performed a systematic review with the search criterion (Glioblastoma OR Glioma) AND (Therapy OR Therapeutic) AND (Nanoparticle) AND (Antiangiogenic OR Angiogenesis OR Anti-angiogenic) in Pubmed, Scopus, and Cochrane databases, in which 312 articles were identified; of these, only 27 articles were included after selection and analysis of eligibility according to the inclusion and exclusion criteria. The data of the articles were analyzed in five contexts: the characteristics of the tumor cells; the animal models used to induce GBM for antiangiogenic treatment; the composition of nanoformulations and their physical and chemical characteristics; the therapeutic anti-angiogenic process; and methods for assessing the effects on antiangiogenic markers caused by therapies. The articles included in the review were heterogeneous and varied in practically all aspects related to nanoformulations and models. However, there was slight variance in the antiangiogenic effect analysis. CD31 was extensively used as a marker, which does not provide a view of the effects on the most diverse aspects involved in angiogenesis. Therefore, the present review highlighted the need for standardization between the different approaches of antiangiogenic therapy for the GBM model that allows a more effective meta-analysis and that helps in future translational studies.

show abstract

The future of peptides in cancer treatment

Cited by 73 publications

References 33 publications

pH- and concentration-dependent supramolecular self-assembly of a naturally occurring octapeptide

pH- and concentration-dependent supramolecular self-assembly of a naturally occurring octapeptide

How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs

Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations

Contact Info

Product

Resources

About